Pfizer Inc said on Monday it finalized a deal with Japan's Taisho Pharma to jointly research and develop TS-032, a new schizophrenia drug discovered by Taisho.
Taisho will grant Pfizer exclusive development and commericalization rights for the drug outside Japan. Pfizer said it will pay Taisho an initial payment of $22 million, as well as royalties and milestone payments depending on whether the drug is approved by regulators and is launched
Taisho will grant Pfizer exclusive development and commericalization rights for the drug outside Japan. Pfizer said it will pay Taisho an initial payment of $22 million, as well as royalties and milestone payments depending on whether the drug is approved by regulators and is launched
No comments:
Post a Comment